Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 889-898

  Mori, N ^a   Kyo, S ^a   Nakamura, M ^a   Hashimoto, M ^a   Maida, Y ^a   Mizumoto, Y ^a   Takakura, M ^a   Ohno, S ^b   Kiyono, T ^c   Inoue, M ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

endometrial cancer; HER 2; paclitaxel; survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; ENDOMETRIUM CANCER; FEMALE; GENE AMPLIFICATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KNOCKOUT GENE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; ENDOMETRIAL NEOPLASMS; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; SURVIVAL; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; PACLITAXEL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77956422347     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605805     Document Type: Article

References (32)

1. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N (2005) Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65: 11018-11025
2. Cao C, Lu S, Sowa A, Kivlin R, Amaral A, Chu W, Yang H, Di W, Wan Y (2008) Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett 266: 249-262
3. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40
4. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI (1994) The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109-2123
5. Ejskjaer K, Sørensen BS, Poulsen SS, Forman A, Nexø E, Mogensen O (2007) Expression of the epidermal growth factor system in endo-metrioid endometrial cancer. Gynecol Oncol 104: 158-167 (Pubitemid 46054118)
6. Enomoto T, Fujita M, Inoue M, Nomura T, Shroyer KR (1993) Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53: 1883-1888
7. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E (2004) AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94: 785-795
8. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E (2008) Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13: 259-271
9. Gamett DC, Greene T, Wagreich AR, Kim HH, Koland JG, Cerione RA (1995) Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85. J Biol Chem 270: 19022-19027
10. Goldman R, Levy RB, Peles E, Yarden Y (1990) Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29: 11024-11028
11. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH (2006) PIK3CA and PTEN mutations in uterine endo-metrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932-5935
12. Kanaya T, Kyo S, Sakaguchi J, Maida Y, Nakamura M, Takakura M, Hashimoto M, Mizumoto Y, Inoue M (2005) Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population. Am J Clin Pathol 124: 89-96
13. Kim J, Lee C, Foxworth A, Waldman T (2004) B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res 64: 1932-1937
14. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z (2003) HER2/PI-3K/AKT activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212
15. Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N, Inoue M (2003) Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 163: 2259-2269
16. Marshall CJ (1999) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185
17. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M (2007) Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98: 652-658
18. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT (1992) Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 52: 2777-2781
19. Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M (2007) Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosis. Cancer Sci 98: 1881-1888
20. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24: 2376-2385
21. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924-930
22. Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673
23. Olayioye MA (2001) Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3: 385-389
24. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167
25. Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D (2009) MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/AKT pathway and tumor growth in prostate cancer. BMC Cancer 9: 142
26. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554 (Pubitemid 38541907)
27. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430
28. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940
29. Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M, Llecha N, Palacios J, Prat J, Matias-Guiu X (2006) PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37: 1465-1472
30. Wada T, Qian XL, Greene MI (1990) Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339-1347
31. Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S, Ma D (2009) Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett 273: 257-265
32. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365